Show simple item record

dc.contributor.authorDeconinck, Eric
dc.contributor.authorMiadi-Fargier, Houda
dc.contributor.authorLe Pen, Claude
dc.contributor.authorBrice, Pauline
dc.date.accessioned2012-09-12T12:03:12Z
dc.date.available2012-09-12T12:03:12Z
dc.date.issued2010
dc.identifier.urihttps://basepub.dauphine.fr/handle/123456789/9971
dc.language.isoenen
dc.subjectMedical costen
dc.subjecttherapiesen
dc.subjectoncologyen
dc.subject.ddc334en
dc.subject.classificationjelI12en
dc.subject.classificationjelI11en
dc.titleCost effectiveness of rituximab maintenance therapy in follicular lymphoma: long-term economic evaluationen
dc.typeArticle accepté pour publication ou publié
dc.contributor.editoruniversityotherUniversité de Franche-Comté, Hematology-CHU Jean Minjoz, Besançon;France
dc.description.abstractenBACKGROUND: Rituximab maintenance therapy was shown to significantly extend overall survival (OS) and progression-free survival (PFS) in relapsed/refractory follicular lymphoma (FL) in the pivotal EORTC 20981 trial. OBJECTIVE: To assess the long-term costs and cost effectiveness of rituximab maintenance therapy after induction therapy versus current standard practice (observation) from the French National Health Service perspective. METHODS: A lifetime transition model was developed comparing rituximab maintenance with observation. PFS and OS were obtained from the EORTC 20981 trial with a median follow-up of 28 months and extrapolated from 2-year Kaplan-Meier curves using a Weibull distribution. PFS and OS benefits of rituximab were conservatively assumed to last only 5 years. Utility data were obtained from a multicentre observational study using the EQ-5D questionnaire. Direct medical costs were obtained from French official sources. All costs are reported in euro, year 2006 values. RESULTS: The EORTC 20981 study demonstrated that rituximab maintenance was effective in the management of relapsed/refractory FL. The model results showed that life expectancy and QALYs were increased by 22% and 28%, respectively, in patients treated with rituximab. The incremental cost-effectiveness ratios (ICERs) were euro 7612 per life-year gained and euro 8729 per QALY gained. In a one-way sensitivity analysis, most of the ICERs fell within the range of euro 7000-12,000. The results tend to show that rituximab maintenance therapy may be a cost-effective strategy in the management of relapsed/refractory FL in France, with ICERs below those observed for other therapies in the oncology field. The cost of rituximab was partly offset by the lower cost of relapse due to a longer time in the disease-free health state for patients in the rituximab arm.en
dc.relation.isversionofjnlnamePharmacoEconomics
dc.relation.isversionofjnlvol28en
dc.relation.isversionofjnlissue1en
dc.relation.isversionofjnldate2010
dc.relation.isversionofjnlpages35-46en
dc.relation.isversionofdoihttp://dx.doi.org/10.2165/11314070-000000000-00000en
dc.relation.isversionofjnlpublisherFCCPen
dc.subject.ddclabelEconomie socialeen
dc.relation.forthcomingnonen
dc.relation.forthcomingprintnonen


Files in this item

FilesSizeFormatView

There are no files associated with this item.

This item appears in the following Collection(s)

Show simple item record